$LEXX News

Lexaria Celebrates its 70th Patent Award

Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule

Lexaria Bioscience Completes Enrollment And Continues Dosing On Schedule In Two Oral Semaglutide Pilot Study Comparing DehydraTECH Formulations To Wegovy Tablets

Lexaria Announces Results from Animal Study GLP-1-A26-1

Lexaria Bioscience Announces Results From Animal Study GLP-1-A26-1 Evaluating Both DehydraTECH-CBD Compositions And DehydraTECH-Semaglutide; Unfortunately, The DHT-SEMA Concentrations In Brain Tissue Were All At Levels Below The Lower Limit Of Quantitation Of The Bioassay Utilized In This Study

GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications

Lexaria Updates Financial Position

Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

LEXX: Introducing DehydraTECH 3.0

Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Lexaria Receives USD$2.6 Million Tax Rebate Payment

Lexaria Bioscience Announces Australian Tax Office Pays AU$3.667M In Tax Rebate To Co.

Lexaria Bioscience Completes Blood Plasma Pharmacokinetic Bioanalysis Testing In Its 2026 Animal Study 2 Evaluating Oral Delivery Of 2 Next-Generation GLP-Drugs, Amycretin And Retatrutide, In A Total Of 18 Different Study Arms In Dogs Following Use Of Its DehydraTECH Drug Delivery Platform

Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know

Lexaria Enters a Material Transfer Agreement With PegBio

Lexaria Bioscience Enters Material Transfer Agreement With Pegbio To Investigate LEXX's DehydraTECH Technology With A Proprietary Pegbio Molecule Under Development For The GLP-1 Industry

Lexaria Announces Effective Date for Reverse Stock Split

LEXX: Dosing Started for Animal & Human GLP-1 Studies

Lexaria Bioscience Q3 EPS $(0.08) Beats $(0.09) Estimate